Trials that use: Time-to-event endpoints
New to this method? Read the tutorial →
343 results
- CARE-MS IIndependent statistical analysis of CARE-MS I, a randomized phase 3 trial comparing alemtuzumab with interferon beta-1a in relapsing-remitting multiple sclerosis, including endpoint definitions, hazard ratios, rate ratios, longitudinal analyses, and statistical interpretation.
- CARE-MS IIComplete statistical analysis of CARE-MS II, a randomized phase 3 trial comparing alemtuzumab with interferon beta-1a in relapsing-remitting multiple sclerosis, including primary endpoints, statistical methods, secondary analyses, safety, and interpretation.
- CARMELINAIndependent statistical analysis of CARMELINA (NCT01897532), a randomized phase 4 trial of linagliptin versus placebo in patients with type 2 diabetes mellitus, including time-to-event methodology, non-inferiority testing, cardiovascular and renal endpoints, safety,…
- CAROLINAIndependent statistical analysis of the CAROLINA phase 3 trial comparing linagliptin with glimepiride in patients with type 2 diabetes, including non-inferiority testing, cardiovascular outcomes, glycaemic control, ANCOVA, Cox regression, and logistic regression.
- CASPIANIndependent statistical analysis of CASPIAN, the randomized phase 3 trial of durvalumab with platinum-based chemotherapy in untreated extensive-stage small cell lung cancer, including overall survival, progression-free survival, response, statistical methodology, and interpretation.
- CASSIOPEIAA complete statistical analysis of the phase 3 CASSIOPEIA trial evaluating daratumumab in transplant-eligible participants with previously untreated multiple myeloma, including trial design, primary endpoints, reported statistical analyses, safety, and interpretation.
- CATNONIndependent statistical analysis of CATNON (NCT00626990), a randomized phase 3 trial evaluating concomitant and adjuvant temozolomide in anaplastic glioma without 1p/19q loss of heterozygosity.
- CELESTIALIndependent statistical analysis of the phase 3 CELESTIAL trial of cabozantinib versus placebo in hepatocellular carcinoma after prior sorafenib, including overall survival, progression-free survival, objective response, trial design, and statistical methodology.
- CheckMate-026Independent statistical analysis of CheckMate-026, a randomized phase 3 trial of nivolumab versus investigator's choice chemotherapy as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer.
- CheckMate-037Independent statistical analysis of CheckMate-037, a randomized phase 3 trial of BMS-936558 (nivolumab) versus Investigator's Choice in unresectable or metastatic melanoma.
- CheckMate-057Independent statistical analysis of CheckMate-057, a randomized phase 3 trial comparing nivolumab with docetaxel in previously treated metastatic non-squamous non-small cell lung cancer, including overall survival, hazard ratio, log-rank testing, and interpretation.
- CheckMate-078Independent statistical analysis of CheckMate-078, a randomized phase 3 trial comparing nivolumab with docetaxel in previously treated advanced or metastatic non-small cell lung cancer.
- CheckMate-141Independent statistical analysis of CheckMate-141, the randomized phase 3 trial of nivolumab versus investigator's choice therapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
- CheckMate-227Independent statistical analysis of CheckMate-227 (NCT02477826), including randomized trial design, time-to-event endpoints, hazard ratios, confidence intervals, statistical methodology, safety, and interpretation.
- CheckMate-238Independent statistical analysis of CheckMate-238, a randomized phase 3 trial of nivolumab versus ipilimumab for prevention of melanoma recurrence after complete resection of stage IIIb/c or stage IV melanoma.
- CheckMate-274Independent statistical analysis of CheckMate-274 (NCT02632409), a randomized phase 3 trial of nivolumab versus placebo following surgery for bladder or upper urinary tract cancer, including its disease-free survival endpoints, Cox model results,…
- CheckMate-459Independent statistical analysis of CheckMate-459, a randomized phase 3 trial comparing nivolumab with sorafenib as first treatment in advanced hepatocellular carcinoma, including overall survival, response, progression-free survival, statistical methods, and interpretation.
- CheckMate-649Independent statistical analysis of CheckMate-649, a randomized phase 3 trial of nivolumab plus chemotherapy versus chemotherapy in stomach cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, focusing on overall survival, progression-free survival, hazard…
- CheckMate-651Independent statistical analysis of CheckMate-651, a randomized phase 3 trial of nivolumab plus ipilimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and…
- CheckMate-76KComplete statistical analysis of CheckMate-76K, the randomized phase 3 trial of nivolumab versus placebo for prevention of recurrent melanoma after complete resection of stage IIB/C melanoma.
- CheckMate-816Independent statistical analysis of CheckMate-816, a randomized phase 3 trial of nivolumab plus platinum-doublet chemotherapy versus chemotherapy alone in early-stage non-small cell lung cancer.
- CheckMate-914Independent statistical analysis of CheckMate-914, a randomized phase 3 trial of nivolumab, nivolumab plus ipilimumab, and placebo in participants with localized renal cell carcinoma after surgery.
- CheckMate-9ERIndependent statistical analysis of CheckMate-9ER, the phase 3 randomized trial of nivolumab combined with cabozantinib versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma.
- CIRTComplete statistical analysis of CIRT (NCT01594333), a randomized phase 3 trial of methotrexate versus placebo in cardiovascular disease, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing, stratification, multiplicity, safety, and statistical…
- CLEARIndependent statistical analysis of the phase 3 CLEAR trial of lenvatinib plus everolimus or lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma, focusing on progression-free survival and the trial's time-to-event…
- CLEAR OutcomesIndependent statistical analysis of CLEAR Outcomes, the randomized phase 3 trial of bempedoic acid versus placebo in statin-intolerant participants with or at high risk for cardiovascular disease, including MACE, secondary time-to-event endpoints,…
- CLEOPATRAIndependent statistical analysis of CLEOPATRA, the randomized phase 3 trial of pertuzumab plus trastuzumab and docetaxel versus placebo plus trastuzumab and docetaxel in previously untreated HER2-positive metastatic breast cancer.
- CLL14Independent statistical analysis of the CLL14 phase 3 trial comparing obinutuzumab plus venetoclax with obinutuzumab plus chlorambucil in chronic lymphocytic leukemia, including time-to-event and response analyses.
- CLOVERSIndependent statistical analysis of the CLOVERS phase 3 trial comparing restrictive fluids with liberal fluids in patients with septic shock, including trial design, primary mortality analysis, secondary outcomes, statistical methodology, and interpretation.
- COAPTIndependent statistical analysis of the COAPT trial (NCT01626079), evaluating MitraClip in symptomatic heart failure with functional mitral regurgitation, including trial design, primary safety analysis, recurrent hospitalization, win ratio methodology, and statistical interpretation.
- CodeBreaK 200Independent statistical analysis of CodeBreaK 200, a randomized phase 3 trial comparing AMG 510 (sotorasib) with docetaxel in KRAS G12C-mutated advanced or metastatic NSCLC, including progression-free survival, hazard ratios, confidence intervals, log-rank…
- COMBI-ADAn independent statistical analysis of the phase 3 COMBI-AD trial of dabrafenib with trametinib in high-risk BRAF V600 mutation-positive melanoma, including trial design, relapse-free survival, secondary time-to-event analyses, statistical methods, and interpretation.
- COMBI-vIndependent statistical analysis of the COMBI-v phase 3 trial of dabrafenib plus trametinib versus vemurafenib in unresectable or metastatic BRAF V600E/K cutaneous melanoma, including trial design, time-to-event endpoints, hazard ratios, confidence intervals,…
- COMET-1Independent statistical analysis of COMET-1, the randomized phase 3 trial of cabozantinib versus prednisone in men with metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone or MDV3100.
- COMPARZIndependent statistical analysis of the COMPARZ phase 3 trial comparing pazopanib with sunitinib in locally advanced and/or metastatic renal cell carcinoma, including its progression-free survival endpoint, non-inferiority framework, Cox model, and reported…
- COMPASSIndependent statistical analysis of the COMPASS phase 3 trial of rivaroxaban-based antithrombotic treatment in coronary or peripheral artery disease, including trial design, time-to-event endpoints, hazard ratios, safety outcomes, statistical methods, and interpretation.
- COMPASS-2Independent statistical analysis of COMPASS-2, evaluating bosentan added to sildenafil versus sildenafil monotherapy in pulmonary arterial hypertension, including time-to-event, functional, biomarker, quality-of-life, and safety results.
- CONTACT-01Independent statistical analysis of CONTACT-01, a randomized phase 3 trial of atezolizumab plus cabozantinib versus docetaxel in metastatic non-small cell lung cancer previously treated with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy.
- CONTACT-03Independent statistical analysis of CONTACT-03, a randomized phase 3 trial of atezolizumab plus cabozantinib versus cabozantinib alone in participants with advanced renal cell carcinoma after immune checkpoint inhibitor treatment.
- COSMIC-312Complete statistical analysis of COSMIC-312, the randomized phase 3 trial of cabozantinib plus atezolizumab versus sorafenib in previously untreated advanced hepatocellular carcinoma, including its time-to-event endpoints, hazard ratios, confidence intervals, p-values, and…
- COSMIC-313Independent statistical analysis of COSMIC-313, a randomized phase 3 trial of cabozantinib with nivolumab and ipilimumab versus placebo with nivolumab and ipilimumab in previously untreated advanced or metastatic renal cell carcinoma.
- COU-AA-301Independent statistical analysis of COU-AA-301, a randomized phase 3 trial of abiraterone acetate in castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy, covering overall survival, progression, PSA response, trial design, and statistical…
- COVACTAIndependent statistical analysis of the randomized phase 3 COVACTA trial evaluating tocilizumab versus placebo in patients with severe COVID-19 pneumonia, including endpoint definitions, reported treatment effects, confidence intervals, p-values, and statistical methodology.
- CREDENCEComplete statistical analysis of CREDENCE, the randomized phase 3 trial evaluating canagliflozin versus placebo for renal and cardiovascular outcomes in participants with type 2 diabetes and diabetic nephropathy.
- CRESTIndependent statistical analysis of CREST (NCT00004732), a randomized double-masked trial comparing carotid endarterectomy with carotid artery stenting for patients with carotid stenosis.
- CRYSTALIndependent statistical analysis of the CRYSTAL phase 3 trial of cetuximab plus FOLFIRI versus FOLFIRI alone in EGFR-expressing metastatic colorectal cancer, including progression-free survival, overall survival, response, statistical methods, and interpretation.
- CRYSTAL-AFIndependent statistical analysis of CRYSTAL-AF, evaluating continuous cardiac monitoring with an insertable cardiac monitor for atrial fibrillation detection after cryptogenic stroke or transient ischemic attack.
- D-CAREIndependent statistical analysis of the D-CARE phase 3 trial of denosumab as adjuvant treatment for women with high-risk early breast cancer, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, stratified log-rank…
- DAPA-CKDIndependent statistical analysis of the randomized phase 3 DAPA-CKD trial evaluating dapagliflozin versus placebo for renal and cardiovascular outcomes in patients with chronic kidney disease.
- DAPA-HFIndependent statistical analysis of the DAPA-HF phase 3 trial evaluating dapagliflozin in patients with chronic heart failure with reduced ejection fraction, including trial design, endpoints, Cox models, win ratio, rate ratio, results,…